复发性Ta低级别非肌层浸润性膀胱癌:有哪些选择?
本文以一例60岁女性中危非肌层浸润性膀胱癌患者为例,该患者经序贯丝裂霉素C和卡介苗治疗后仍多次复发,讨论后续选择包括重复经尿道膀胱肿瘤电切术并继续监测、继续相同膀胱内治疗、器械辅助给药或参加临床试验,并指出领域最大未满足需求是缺乏分子标志物来筛选侵袭性策略患者。
要点
- 复发性Ta低级别肿瘤属中危非肌层浸润性膀胱癌,复发风险高但进展风险低。
- 该患者经序贯丝裂霉素C和卡介苗治疗后仍多次复发。
- 除非复发显示疾病进展迹象,否则不应需要根治性膀胱切除术。
核心结论
- 复发性Ta低级别中危非肌层浸润性膀胱癌的治疗选择包括重复经尿道膀胱肿瘤电切术并继续监测、继续相同膀胱内治疗、器械辅助给药或参加临床试验。
- 领域最大未满足需求是缺乏分子标志物来帮助选择侵袭性策略的患者。
- 除非复发显示疾病进展迹象,否则不应需要根治性手术(膀胱切除)。
研究设计与样本
- 本文为病例讨论,报告一例60岁女性中危非肌层浸润性膀胱癌患者。
主要发现
- 该患者经序贯丝裂霉素C和卡介苗治疗后仍出现多次复发。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Recurrent low-grade Ta tumours, classified as intermediate-risk non-muscle-invasive bladder cancer (NMIBC), have a high risk of recurrence but a low risk of progression. This case presents a 60-yr-old female with intermediate-risk NMIBC who has been treated with sequential courses of mitomycin C followed by bacillus Calmette-Guérin (BCG). She continued to develop multiple episodes of recurrence. The discussion addresses whether the best course is repeat transurethral resection of the bladder with continued monitoring, more of the same intravesical treatments, new methods of applying these treatments, or novel treatments that might involve enrolling the patient in a clinical trial. The biggest unmet need in the field comes from the lack of a molecular marker that could help select patients for aggressive strategies. PATIENT SUMMARY: Following treatment of intermediate-risk non-muscle-invasive bladder cancer with a fairly standard course of intravesical drug therapy, the patient, a relatively young woman, continued to develop recurrences of the bladder cancer. The authors discuss whether the best next course is "more of the same", device-assisted application of these treatments, or perhaps one of the new, still investigatory treatment approaches. Radical surgery (removal of the bladder) should not be necessary unless the recurrences show signs of disease progression.
引用
- Rouprêt M, Malmstrom PU, Black P, et al. Recurrent Ta Low-grade Non-muscle-invasive Bladder Cancer: What Are the Options? Eur Urol Oncol. 2019. PMID: 31239237. doi:10.1016/j.euo.2019.06.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。